Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk

CVD-T2DM

Endocrine Society Guidelines App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/58913

Contents of this Issue

Navigation

Page 8 of 11

Contraindications Absolute: Active or chronic liver disease Pregnancy, lactation or desire to become pregnant Relative (statin specific: see individual PI): Concomitant use of certain drugs (Cyclosporine, macrolide antibiotics, various antifungal agents and cytochrome P-450 inhibitors [fibrates and niacin should be used with appropriate caution]) Absolute: Dysbetalipoproteinemia TG > 400 mg/dL Relative: TG > 200 mg/dL Absolute: Unexplained hepatic dysfunction, active peptic ulcer, arterial bleeding Relative: DM Hyperuricemia Peptic ulcer disease Absolute: Severe renal dysfunction or dialysis Active liver disease & unexplained aminase elevation Gall bladder disease Nursing mothers Clinical Trial Results Reduced major coronary events, CHD deaths, need for coronary procedures, stroke, and total mortality Reduced major coronary events and CHD deaths Reduced major coronary events and possibly total mortality Reduced major coronary events Previous sensitivity No outcome trials completed Relative: Fish hypersensitivity Nonfatal MI reductions in Japanese patients on low dose statin Improved mortality and reduced sudden death in MI patients and those with CHF

Articles in this issue

Archives of this issue

view archives of Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk - CVD-T2DM